Peter Radovich
2023
In 2023, Peter Radovich earned a total compensation of $2.4M as President and Chief Operating Officer at Mirum Pharmaceuticals, a 52% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $363,600 |
|---|---|
| Option Awards | $977,107 |
| Salary | $505,000 |
| Stock Awards | $508,577 |
| Other | $13,200 |
| Total | $2,367,484 |
Radovich received $977.1K in option awards, accounting for 41% of the total pay in 2023.
Radovich also received $363.6K in non-equity incentive plan, $505K in salary, $508.6K in stock awards and $13.2K in other compensation.
Rankings
In 2023, Peter Radovich's compensation ranked 410th out of 2,647 executives tracked by ExecPay. In other words, Radovich earned more than 84.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 410 out of 2,647 | 85th |
Division Manufacturing | 233 out of 1,447 | 84th |
Major group Chemicals And Allied Products | 166 out of 817 | 80th |
Industry group Drugs | 163 out of 783 | 79th |
Industry Pharmaceutical Preparations | 102 out of 555 | 82nd |
Source: SEC filing on April 23, 2024.
Radovich's colleagues
We found two more compensation records of executives who worked with Peter Radovich at Mirum Pharmaceuticals in 2023.
News
Mirum Pharmaceuticals CEO Christopher Peetz's 2023 pay jumps 47% to $6.5M
April 23, 2024
Mirum Pharmaceuticals CEO Christopher Peetz's 2022 pay rises 7% to $4.4M
May 1, 2023
Mirum Pharmaceuticals CEO Christopher Peetz's 2021 pay jumps 38% to $4.1M
April 22, 2022
Mirum Pharmaceuticals CEO Christopher Peetz's 2020 pay falls 52% to $3M
April 14, 2021